![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Simeprevir plus daclatasvir and sofosbuvir in treatment-naïve and treatment-experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: interim results from the Phase II IMPACT study
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Lawitz E,1 Poordad F,1 Gutierrez J,1 Kakuda T,2 Picchio G,3 De La Rosa G,4 Beets G,5 Vandevoorde A,5 Van Remoortere P,2 Jacquemyn B,5 Quinn G,5 Luo D,2 Ouwerkerk-Mahadevan S,6 Vijgen L,5 Van Eygen V,5 Beumont M6
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2Janssen Research & Development LLC, Titusville, NJ, USA; 3Infectious Diseases, Janssen Research & Development, San Francisco, CA, USA; 4Janssen Global Services, LLC, Titusville, NJ, USA; 5Janssen Infectious Diseases BVBA, Beerse, Belgium; 6Janssen Research & Development, Beerse, Belgium
![EASL1.gif](../images/042415/042415-9/EASL1.gif)
![EASL2.gif](../images/042415/042415-9/EASL2.gif)
![EASL3.gif](../images/042415/042415-9/EASL3.gif)
![EASL4.gif](../images/042415/042415-9/EASL4.gif)
![EASL5.gif](../images/042415/042415-9/EASL5.gif)
![EASL6.gif](../images/042415/042415-9/EASL6.gif)
![EASL7.gif](../images/042415/042415-9/EASL7.gif)
![EASL8.gif](../images/042415/042415-9/EASL8.gif)
![Pharm.gif](../images/042415/042415-9/Pharm.gif)
![EASL9.gif](../images/042415/042415-9/EASL9.gif)
![EASL10.gif](../images/042415/042415-9/EASL10.gif)
![EASL11.gif](../images/042415/042415-9/EASL11.gif)
![EASL12.gif](../images/042415/042415-9/EASL12.gif)
![EASL13.gif](../images/042415/042415-9/EASL13.gif)
![EASL14.gif](../images/042415/042415-9/EASL14.gif)
![EASL15.gif](../images/042415/042415-9/EASL15.gif)
![EASL16.gif](../images/042415/042415-9/EASL16.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|